We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Recurrent or refractory Classical Hodgkin Lymphoma (cHL) refers to a type of cancer that affects the lymphatic system, where the disease either returns after treatment or does not respond to initial therapies. This condition can lead to symptoms such as swollen lymph nodes, fever, night sweats, and unexplained weight loss.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.